Table 1.
Antimicrobial susceptibility results for the type strain and 13 clinical isolates of Gordonia polyisoprenivorans
| Antimicrobial agent | MIC (μg/ml)a |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G. polyisoprenivorans ATCC BAA-14T | Isolate W8130 | IsolateW8137 | Isolate W8277 | Isolate W8350 | Isolate W8398 | Isolate W8446 | Isolate W8488 | Isolate W8560 | Isolate W8859 | Isolate W8876 | Isolate W9085 | Isolate X0357 | Isolate X0406 | |
| Amikacin | £0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | 0.5 (S) | ≤0.25 (S) | ≤0.25 (S) | 1 (S) | ≤0.25 (S) | ≤0.25 (S) | <0.25 (S) | <0.25 (S) |
| Amoxicillin-clavulanate | ≤0.5/0.25 (S) | ≤0.5/0.25 (S) | ≤0.5/0.25 (S) | ≤0.5/0.25 (S) | ≤0.5/0.25 (S) | 1/0.5 (S) | 8/4 (S) | 1/0.5 (S) | ≤0.5/0.25 (S) | 1/0.5 (S) | ≤0.5/0.25 (S) | ≤0.5/0.25 (S) | <0.5/0.25 (S) | <0.25/0.5 (S) |
| Ampicillin | ≤0.5 (S) | 1 (S) | ≤0.5 (S) | ≤0.5 (S) | 1 (S) | 1 (S) | 4 (S) | ≤0.5 (S) | ≤0.5 (S) | 4 (S) | ≤0.5 (S) | ≤0.5 (S) | <0.5 (S) | <0.05 (S) |
| Ceftriaxone | ≤1 (S) | ≤1 (S) | ≤1 (S) | ≤1 (S) | 2 (S) | 4 (S) | 8 (S) | ≤1 (S) | ≤1 (S) | 8 (S) | ≤1 (S) | ≤1 (S) | <1 (S) | <1 (S) |
| Ciprofloxacin | ≤0.06 (S) | 0.13 (S) | ≤0.06 (S) | ≤0.06 (S) | 0.13 (S) | 0.13 (S) | 2 (I) | 0.13 (S) | 0.13 (S) | 0.5 (S) | 0.5 (S) | ≤0.06 (S) | <0.06 (S) | <0.06 (S) |
| Clarithromycin | ≤0.25 (S) | >32 (R) | 8 (R) | >32 (R) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | 8 (R) | 4 (I) |
| Imipenem | 1 (S) | 0.5 (S) | 0.5 (S) | 0.5 (S) | 1 (S) | 2 (S) | 2 (S) | 0.5 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | <0.25 (S) |
| Linezolid | 2 (S) | 1 (S) | 1 (S) | 2 (S) | 2 (S) | 2 (S) | 4 (S) | 2 (S) | 1 (S) | 4 (S) | 2 (S) | 2 (S) | 1 (S) | 2 (S) |
| Minocycline | 1 (S) | 2 (I) | 1 (S) | 0.25 (S) | 2 (I) | 4 (I) | 2 (I) | 2 (I) | 0.5 (S) | 1 (S) | 1 (S) | 1 (S) | 0.25 (S) | 1 (S) |
| Tigecyclineb | ≤0.13 (S) | 4 (I) | 2 (S) | 0.25 (S) | 4 (I) | 8 (R) | 2 (S) | 4 (I) | 2 (S) | 4 (I) | 1 (S) | 2 (S) | <0.13 (S) | 2 (S) |
| Trimethoprim-sulfamethoxazole | 4/76 (R) | 0.5/9.5 (S) | 0.25/4.8 (S) | 8/152 (R) | 4/76 (R) | 1/19 (S) | >8/152 (R) | >8/152 (R) | 1/19 (S) | >8/152 (R) | >8/152 (R) | 4/76 (R) | 0.5/9.5 (S) | 0.5/9.5 (S) |
| Vancomycin | 2 (S) | 1 (S) | 1 (S) | 1 (S) | 1 (S) | 2(S) | 1 (S) | ≤0.5 (S) | 1 (S) | 1 (S) | 1 (S) | 1 (S) | 1 (S) | 1 (S) |
a
Abbreviations: S, susceptible; I, intermediate; R, resistant. The MIC interpretive breakpoints were those of the CLSI 2003 M24-A standard (2).
b
Tigecycline breakpoints have not been determined for nocardiae and other aerobic actinomycetes; those proposed by FDA for Enterobacteriaceae were used.